Could BRAF inhibition be a viable neoadjuvant strategy?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Findings of a recent study suggest that BRAF inhibition may be effective as a neoadjuvant therapy in patients with advanced locoregional BRAF V600E mutant melanoma.

Study Design

  • Analysis of outcomes in patients with locoregional BRAF V600E-mutant melanoma who received BRAF inhibitor (BRAFi) therapy at Moffitt Cancer Center.

  • 15 patients: 11 received vemurafenib alone; 4 who received combination dabrafenib + trametinib.

Key Results

  • 25.4 months median follow-up.

  • 73.3% objective response (RECIST).

  • Pathologic responses: complete: 2 patients; partial: 2 patients; none: 2 patients.

  • 6 patients underwent resection f...